CD97 neutralisation increases resistance to collagen-induced arthritis in mice

Arthritis Research and Therapy

Volumn 8, Issue 5, 2006, Pages

  Kop, Else N ^a   Adriaansen, Janik ^a   Smeets, Tom J M ^a   Vervoordeldonk, Margriet J ^a   van Lier, René A W ^a   Hamann, Jörg ^a   Tak, Paul P ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD97 PROTEIN, MOUSE; INTERLEUKIN 6; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY;

ANIMAL; ARTHRITIS, EXPERIMENTAL; BLOOD; DBA MOUSE; DISEASE MODEL; IMMUNOLOGY; IMMUNOTHERAPY; JOINT; MALE; METABOLISM; MOUSE; PATHOLOGY; PROCEDURES; SYNOVIUM; TH1 CELL; TH2 CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; ARTHRITIS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; IMMUNOTHERAPY; INTERLEUKIN-6; JOINTS; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED DBA; SYNOVIAL MEMBRANE; TH1 CELLS; TH2 CELLS;

EID: 36048935193     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2049     Document Type: Article

References (33)

1. Tak PP: Examination of the synovium and synovial fluid. In Rheumatoid Arthritis: Frontiers in Pathogenesis and Treatment 2nd edition. Edited by: Firestein GS, Panayi GS, Wolheim FA. Oxford: Oxford University Press; 2006:229-241.
2. Firestein GS: Evolving concepts of rheumatoid arthritis. Nature 2003, 423:356-361.
3. Kwakkenbos MJ, Kop EN, Stacey M, Matmati M, Gordon S, Lin HH, Hamann J: The EGF-TM7 family: A postgenomic view. Immunogenetics 2004, 55:655-666.
4. Hamann J, Eichler W, Hamann D, Kerstens HM, Poddighe PJ, Hoovers JM, Hartmann E, Strauss M, Van Lier RA: Expression cloning and chromosomal mapping of the leukocyte activation antigen CD97, a new seven-span transmembrane molecule of the secretion receptor superfamily with an unusual extracellular domain. J Immunol 1995, 155 1942-1950.
5. Gray JX, Haino M, Roth MJ, Maguire JE, Jensen PN, Yarme A, Stetler-Stevenson MA, Siebenlist U, Kelly K: CD97 is a processed, seven-transmembrane, heterodimeric receptor associated with inflammation J Immunol 1996, 157:5438-5447.
6. Hamann J, Vogel B, Van Schijndel GM, Van Lier RA: The sevenspan transmembrane receptor CD97 has a cellular ligand (CD55, DAF). J Exp Med 1996, 184:1185-1189.
7. Hamann J, Stortelers C, Kiss-Toth E, Vogel B, Eichler W, Van Lier RA: Characterization of the CD55 (DAF)-binding site on the seven-span transmembrane receptor CD97. Eur J Immunol 1998, 28 1701-1707.
8. Stacey M, Chang GW, Davies JQ, Kwakkenbos MJ, Sanderson RD, Hamann J, Gordon S, Lin HH: The epidermal growth factorlike domains of the human EMR2 receptor mediate cell attachment through chondroitin sulfate glycosaminoglycans. Blood 2003, 102:2916-2924.
9. Kwakkenbos MJ, Pouwels W, Matmati M, Stacey M, Lin HH, Gordon S, Van Lier RA, Hamann J: Expression of the largest CD97 and EMR2 isoforms on leukocytes facilitates a specific interaction with chondroitin sulfate on B cells. J Leukoc Biol 2005, 77:112-119.
10. Wang T, Ward Y, Tian L, Lake R, Guedez L, Stetler-Stevenson WG, Kelly K: CD97, an adhesion receptor on inflammatory cells, stimulates angiogenesis through binding integrin counter receptors on endothelial cells. Blood 2005, 105:2836-2844.
11. Hamann J, Wishaupt JO, Van Lier RA, Smeets TJ, Breedveld FC, Tak PP: Expression of the activation antigen CD97 and its ligand CD55 in rheumatoid synovial tissue. Arthritis Rheum 1999, 42 650-658.
12. Kop EN, Kwakkenbos MJ, Teske GJ, Kraan MC, Smeets TJ, Stacey M, Lin HH, Tak PP, Hamann J: Identification of the epidermal growth factor-TM7 receptor EMR2 and its ligand dermatan sulfate in rheumatoid synovial tissue. Arthritis Rheum 2005, 52:442-450.
13. Bhatia A, Blades S, Cambridge G, Edwards JC: Differential distribution of Fc gamma RIIIa in normal human tissues and colocalization with DAF and fibrillin-1: Implications for immunological microenvironments. Immunology 1998, 94:56-63.
14. Worrall JG, Wilkinson LS, Bayliss MT, Edwards JC: Zonal distribution of chondroitin-4-sulphate/dermatan sulphate and chondroitin-6-sulphate in normal and diseased human synovium. Ann Rheum Dis 1994, 53:35-38.
15. El Gabalawy H, Wilkins J: Beta 1 (CD29) integrin expression in rheumatoid synovial membranes: An immunohistologic study of distribution patterns. J Rheumatol 1993, 20:231-237.
16. Courtenay JS, Dallman MJ, Dayan AD, Martin A, Mosedale B: Immunisation against heterologous type II collagen induces arthritis in mice. Nature 1980, 283:666-668.
17. Leemans JC, te Velde AA, Florquin S, Bennink RJ, de Bruin K, van Lier RA, van der Poll T, Hamann J: The epidermal growth factorseven transmembrane (EGF-TM7) receptor CD97 is required for neutrophil migration and host defense. J Immunol 2004, 172:1125-1131.
18. Gerlag DM, Ransone L, Tak PP, Han Z, Palanki M, Barbosa MS, Boyle D, Manning AM, Firestein GS: The effect of a T cell-specific NF-kappa B inhibitor on in vitro cytokine production and collagen-induced arthritis J Immunol 2000, 165:1652-1658.
19. + myeloid cells. J Immunol 1999, 163:3503-3510.
20. Joosten LA, Helsen MM, Saxne T, Van de Loo FA, Heinegard D, Van den Berg WB: IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. J Immunol 1999, 163 5049-5055.
21. Van Holten J, Reedquist K, Sattonet-Roche P, Smeets TJ, Plater- Zyberk C, Vervoordeldonk MJ, Tak PP: Treatment with recombinant interferon-beta reduces inflammation and slows cartilage destruction in the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Res Ther 2004, 6:R239-R249.
22. Tak PP, Gerlag DM, Aupperle KR, Van de Geest DA, Overbeek M, Bennett BL, Boyle DL, Manning AM, Firestein GS: Inhibitor of nuclear factor kappaB kinase beta is a key regulator of synovial inflammation. Arthritis Rheum 2001, 44:1897-1907.
23. Holmdahl R, Jansson L, Gullberg D, Rubin K, Forsberg PO, Klareskog L: Incidence of arthritis and autoreactivity of anti-col lagen antibodies after immunization of DBA/1 mice with heterologous and autologous collagen II. Clin Exp Immunol 1985, 62:639-646.
24. Stuart JM, Townes AS, Kang AH: Type II collagen-induced arthritis. Ann N Y Acad Sci 1985, 460:355-362.
25. Wick MC, Lindblad S, Klareskog L, Van Vollenhoven RF: Relationship between inflammation and joint destruction in early rheumatoid arthritis: A mathematical description. Ann Rheum Dis 2004, 63:848-852.
26. Danks L, Sabokbar A, Gundle R, Athanasou NA: Synovial macrophage- osteoclast differentiation in inflammatory arthritis. Ann Rheum Dis 2002, 61:916-921.
27. Qian YM, Haino M, Kelly K, Song WC: Structural characterization of mouse CD97 and study of its specific interaction with the murine decay-accelerating factor (DAF, CD55). Immunology 1999, 98 303-311.
28. Hamann J, van Zeventer C, Bijl A, Molenaar C, Tesselaar K, van Lier RA: Molecular cloning and characterization of mouse CD97. Int Immunol 2000, 12:439-448.
29. Miwa T, Maldonado MA, Zhou L, Sun X, Luo HY, Cai D, Werth VP, Madaio MP, Eisenberg RA, Song WC: Deletion of decay-accelerating factor (CD55) exacerbates autoimmune disease development in MRL/lpr mice. Am J Pathol 2002, 161:1077-1086.
30. Lin F, Kaminski HJ, Conti-Fine BM, Wang W, Richmonds C, Medof ME: Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection. J Clin Invest 2002, 110:1269-1274.
31. Lin F, Spencer D, Hatala DA, Levine AD, Medof ME: Decay-accelerating factor deficiency increases susceptibility to dextran sulfate sodium-induced colitis: Role for complement in inflammatory bowel disease. J Immunol 2004, 172:3836-3841.
32. Szekanecz Z, Koch AE: Therapeutic inhibition of leukocyte recruitment in inflammatory diseases. Curr Opin Pharmacol 2004, 4 423-428.
33. Haringman JJ, Tak PP: Chemokine blockade: a new era in the treatment of rheumatoid arthritis? Arthritis Res Ther 2004, 6:93-97.